ON5 Cytotoxic resistance and endocrine therapy

Description

PHCY320 (Oncology) Quiz on ON5 Cytotoxic resistance and endocrine therapy, created by Mer Scott on 06/10/2019.
Mer Scott
Quiz by Mer Scott, updated more than 1 year ago
Mer Scott
Created by Mer Scott about 5 years ago
4
0

Resource summary

Question 1

Question
Primary resistance: No [blank_start]response[blank_end] to administration Acquired resistance: Initial [blank_start]regression[blank_end] –> tumour reappears –> patient [blank_start]relapses[blank_end] Caused by - Alterations in drug [blank_start]metabolism[blank_end] - Modifications to [blank_start]drug target[blank_end]
Answer
  • response
  • regression
  • relapses
  • metabolism
  • drug target

Question 2

Question
Resistance mechanisms: 1. Reduced drug [blank_start]uptake[blank_end] E.g. MTX uptake via reduced folate carrier 2. Alteration of [blank_start]intracellular[blank_end] drug targets e.g. Production of DNA TopII with resistance to [blank_start]anthracyclines[blank_end] 3. Decreased drug concentration ([blank_start][blank_end] prodrug activation) e.g. high GST levels inactivate [blank_start]cisplatin, alkylating agents[blank_end] 4. Increased [blank_start]removal[blank_end] of drug e.g. P glycoprotein and multidrug resistance-related protein with [blank_start]vincas, taxanes, anthracylines[blank_end]
Answer
  • uptake
  • intracellular
  • anthracyclines
  • decreased
  • cisplatin, alkylating agents
  • removal
  • vincas, taxanes, anthracylines

Question 3

Question
Where do resistant cells come from? Theory 1: Only [blank_start]resistant[blank_end] cells survive therapy, and repopulate tumour. Theory 2: Mutations present post-therapy are [blank_start]naturally selected[blank_end] for. Combined model: Escape from [blank_start]normal[blank_end] growth control, [blank_start]mutations[blank_end] present, over time we see structural/biochemical [blank_start]abnormalities[blank_end], cytotoxic therapy then causes resistance. Sensitive drugs with shorter lifespans are therefore [blank_start]less[blank_end] prone to resistance.
Answer
  • resistant
  • naturally selected
  • normal
  • mutations
  • abnormalities
  • less

Question 4

Question
Apparent resistance: Tumour can be sensitive but not show a clinical response due to incorrect [blank_start]scheduling[blank_end]. The interval is too [blank_start]long[blank_end]. Cell-cycle specific agents with short [blank_start]t1/2[blank_end] needed. Anatomical [blank_start]isolation[blank_end] also causes apparent resistance; ALL (acute lymphoblastic leukemia) relapse in children due to failure to penetrate [blank_start]BBB[blank_end].
Answer
  • scheduling
  • long
  • t1/2
  • isolation
  • BBB

Question 5

Question
Chemo principles: Principle 1: Treat [blank_start]rapidly[blank_end]. [blank_start]Radiation/surgery[blank_end] with chemo as an adjuvant successfully only in breast cancer and in children. Principle 2: Treat with a [blank_start]combination[blank_end]. Use drugs with different [blank_start]targets[blank_end]. Will have different unwanted effects - though note there is additive [blank_start]efficacy[blank_end] not [blank_start]toxicity[blank_end]. Alternating regimens [blank_start]decreases[blank_end] toxicity.
Answer
  • rapidly
  • Primary radiation/surgery
  • combination
  • targets
  • efficacy
  • toxicity
  • decreases

Question 6

Question
Endocrine Therapy Principles: Cellular proliferation is influenced by hormones. • [blank_start]Oestrogen[blank_end] – female breast, endometrial carcinoma • [blank_start]Androgen[blank_end] – prostate There is tumour regression following [blank_start]ovariectomy[blank_end].
Answer
  • Oestrogen
  • Androgen
  • ovariectomy

Question 7

Question
Hormonal sensitivity in breast cancer depends on genes, estrogen receptors and growth factor receptors. • ER+ means there will be [blank_start]response[blank_end] to therapy • ER+ AND PgR+ increases your chance of [blank_start]remission[blank_end] Also carry growth factor receptors (GFRs). Inverse correlation: High ER content = few [blank_start]GFRs[blank_end] High GFR content = few [blank_start]ERs[blank_end]
Answer
  • response
  • remission
  • GFRs
  • ERs

Question 8

Question
Choose the incorrect statement.
Answer
  • High estrogen favours growth factor synthesis.
  • Hormone therapy goal is to prevent formation of growth factors.
  • Growth factors lead to mitosis and a reduction in estrogen receptors.

Question 9

Question
Oestrogen receptor antagonists e.g. Tamoxifen, clomiphene citrate, nafoxidine - [blank_start]Selective[blank_end] estrogen receptor modulators (SERM) - [blank_start]Competitively[blank_end] binds to oestrogen receptors • Oestrogenic effects (inhibit [blank_start]bone[blank_end] resorption, stimulates [blank_start]PgR[blank_end] synthesis) • Anti-oestrogenic effects (breast tissue, inhibits synthesis of [blank_start]GF[blank_end]) Example: Tamoxifen, for [blank_start]recurrent, metastatic[blank_end] breast cancer. Is an adjuvant/[blank_start]prevention[blank_end]. Metabolised by CYP2D6, 3A4, metabolites have [blank_start]long[blank_end] t1/2. Unwanted Effects: [blank_start]hot[blank_end] flushes, nausea, amenorrhoea, [blank_start]vaginal[blank_end] bleeding
Answer
  • Selective
  • Competitively
  • bone
  • PgR
  • GF
  • recurrent metastatic
  • prevention
  • long
  • hot
  • vaginal

Question 10

Question
Aromatase inhibitors e.g. Anastrozole, Letrozole, Exemestane (steroid) Aromatase converts androgens to [blank_start]oestrogen[blank_end]; this is the primary mechanism of BC in [blank_start]post[blank_end] menopausal women, so we can inhibit it. For [blank_start]advanced[blank_end] breast cancer. No value if patient is [blank_start]premenopausal[blank_end]. SEs: Stiffness, [blank_start]joint[blank_end] pain, loss of bone mineral [blank_start]density[blank_end] (osteoporosis, bone fractures).
Answer
  • oestrogen
  • post
  • advanced
  • premenopausal
  • joint
  • density

Question 11

Question
Carcinoma of the prostate: Androgens modulate by: • Growth of prostatic [blank_start]epithelium[blank_end] • Production of prostatic [blank_start]fluid[blank_end] • [blank_start]Most[blank_end] prostate cancers arise from epithelium 3 main approaches: 1. Remove [blank_start]primary[blank_end] source 2. Block hormone [blank_start]synthesis[blank_end] (*5 alpha-reductase) 3. Androgen R [blank_start]antagonists[blank_end]
Answer
  • epithelium
  • fluid
  • Most
  • primary
  • synthesis
  • antagonists

Question 12

Question
Lowering androgen levels 1. [blank_start]Surgically[blank_end] (orchidectomy) 2. Chemically using synthetic [blank_start]gonadotrophin[blank_end] releasing hormones - [blank_start]GnRH and LHRH)[blank_end] analogues e.g. goserelin, leuprorelin. Causes initial [blank_start]flare[blank_end] (high [blank_start]LH and FSH[blank_end]) = Downregulation of GnRH [blank_start]receptors[blank_end], loss of sensitivity, suppress [blank_start]androgen[blank_end] formation. Unwanted effects: sexual [blank_start]dysfunction[blank_end], hot [blank_start]flushes[blank_end], growth of [blank_start]breast[blank_end] tissue
Answer
  • Surgically
  • gonadotrophin
  • GnRH and LHRH
  • flare
  • LH and FSH
  • receptors
  • androgen
  • dysfunction
  • flushes
  • breast

Question 13

Question
Antiandrogens e.g. Flutamide can [blank_start]inhibit[blank_end] flare. • [blank_start]Selective[blank_end] antagonist • Prevents [blank_start]testosterone[blank_end] binding to [blank_start]nuclear[blank_end] androgen receptors in [blank_start]prostate[blank_end] Have no effect on [blank_start]pituitary[blank_end] function and so fewer side effects.
Answer
  • inhibit
  • Selective
  • testosterone
  • nuclear
  • prostate
  • pituitary
Show full summary Hide full summary

Similar

Oncology Final MCQs 1- 5th Year PMU
Med Student
Test of Nuclear Medicine- Oncology 5th Year PMU
Med Student
Neurosurgery Module II - Neuro-oncology
Matthew Coulson
Cancer Genetics
Farrah
PATHO LE2: Neoplasia
Jessica Margaux Mercado
HPV Natural history
Nicole Neumann
Introduction to Oncology - Drugs
Ryan Kidd
Approach to childhood malignany
Averil Tam
Hematology
annerao
Oncology
James Sante
Oncology Quiz #1
Mostapha Abdelkader